BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15689452)

  • 21. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
    Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
    Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
    Jhuraney A; Velkova A; Johnson RC; Kessing B; Carvalho RS; Whiley P; Spurdle AB; Vreeswijk MP; Caputo SM; Millot GA; Vega A; Coquelle N; Galli A; Eccles D; Blok MJ; Pal T; van der Luijt RB; Santamariña Pena M; Neuhausen SL; Donenberg T; Machackova E; Thomas S; Vallée M; Couch FJ; Tavtigian SV; Glover JN; Carvalho MA; Brody LC; Sharan SK; Monteiro AN;
    J Med Genet; 2015 Apr; 52(4):224-30. PubMed ID: 25643705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
    Hayes F; Cayanan C; Barillà D; Monteiro AN
    Cancer Res; 2000 May; 60(9):2411-8. PubMed ID: 10811118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.
    Hadjisavvas A; Adamou A; O'Dowd Phanis C; Todd CM; Kitsios P; Kyriacou K; Christodoulou CG
    Oncol Rep; 2002; 9(2):383-6. PubMed ID: 11836613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
    J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
    Machackova E; Damborsky J; Valik D; Foretova L
    Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
    De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
    Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1/2 missense mutations and the value of in-silico analyses.
    Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
    Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families.
    Kim TJ; Lee KM; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
    Oncol Rep; 2006 Mar; 15(3):565-9. PubMed ID: 16465413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
    Augello C; Bruno L; Bazan V; Calò V; Agnese V; Corsale S; Cascio S; Gargano G; Terrasi M; Barbera F; Fricano S; Adamo B; Valerio MR; Colucci G; Sumarcz E; Russo A;
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii30-3. PubMed ID: 16760288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
    Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
    Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of BRCA1 ring finger variants of uncertain significance.
    Sweet K; Senter L; Pilarski R; Wei L; Toland AE
    Breast Cancer Res Treat; 2010 Feb; 119(3):737-43. PubMed ID: 19543972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.